 The objective of the study is to evaluate and compare the frequency and severity of GI adverse events in different dose administration regimens. The patient population consists of low or intermediate int-1 risk myelodysplastic syndrome MDS patients with transfusional iron overload. The study patients are randomized to either a morning dose of 20 mgkgday deferasirox or an evening dose of the same. Patients are then followed up for 6 months for any GI events and are assessed using patient reported outcomes tools e.g. a patient diary. 